OncoMatch/Clinical Trials/NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Is NCT06756035 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CT-95 for mesothelin-expressing tumors.
Treatment: CT-95 — This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Mesothelioma
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Cholangiocarcinoma
Tumor Agnostic
Colorectal Cancer
Biomarker criteria
Required: MSLN expression
Disease stage
Required: Stage IV, NON-RESECTABLE
advanced cancers associated with mesothelin expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MSLN-targeted CD3 therapy
Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
Cannot have received: chimeric antigen receptor T cell therapy
Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
Lab requirements
Blood counts
Kidney function
Liver function
Subjects with adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Context Investigational Site · Denver, Colorado
- Context Investigational Site · Chicago, Illinois
- Context Investigational Site · Grand Rapids, Michigan
- Context Investigational Site · Hackensack, New Jersey
- Context Investigational Site · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify